JP2021019642A5 - - Google Patents

Download PDF

Info

Publication number
JP2021019642A5
JP2021019642A5 JP2020184527A JP2020184527A JP2021019642A5 JP 2021019642 A5 JP2021019642 A5 JP 2021019642A5 JP 2020184527 A JP2020184527 A JP 2020184527A JP 2020184527 A JP2020184527 A JP 2020184527A JP 2021019642 A5 JP2021019642 A5 JP 2021019642A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020184527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021019642A (ja
JP7072622B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021019642A publication Critical patent/JP2021019642A/ja
Publication of JP2021019642A5 publication Critical patent/JP2021019642A5/ja
Application granted granted Critical
Publication of JP7072622B2 publication Critical patent/JP7072622B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020184527A 2017-05-19 2020-11-04 Btlaアゴニスト抗体およびその使用 Active JP7072622B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508,510 2017-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020511876A Division JP6790304B2 (ja) 2017-05-19 2018-05-11 Btlaアゴニスト抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2021019642A JP2021019642A (ja) 2021-02-18
JP2021019642A5 true JP2021019642A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7072622B2 JP7072622B2 (ja) 2022-05-20

Family

ID=62245543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511876A Active JP6790304B2 (ja) 2017-05-19 2018-05-11 Btlaアゴニスト抗体およびその使用
JP2020184527A Active JP7072622B2 (ja) 2017-05-19 2020-11-04 Btlaアゴニスト抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020511876A Active JP6790304B2 (ja) 2017-05-19 2018-05-11 Btlaアゴニスト抗体およびその使用

Country Status (26)

Country Link
US (2) US10604573B2 (cg-RX-API-DMAC7.html)
EP (1) EP3625257A1 (cg-RX-API-DMAC7.html)
JP (2) JP6790304B2 (cg-RX-API-DMAC7.html)
KR (3) KR102294051B1 (cg-RX-API-DMAC7.html)
CN (3) CN110621699B (cg-RX-API-DMAC7.html)
AR (1) AR111752A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018269585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019021547A2 (cg-RX-API-DMAC7.html)
CA (2) CA3064518A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012756A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190521A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000293A (cg-RX-API-DMAC7.html)
EA (1) EA201992460A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19082184A (cg-RX-API-DMAC7.html)
JO (1) JOP20190261A1 (cg-RX-API-DMAC7.html)
MA (1) MA49133A (cg-RX-API-DMAC7.html)
MX (1) MX381033B (cg-RX-API-DMAC7.html)
MY (2) MY197425A (cg-RX-API-DMAC7.html)
NZ (1) NZ758360A (cg-RX-API-DMAC7.html)
PE (1) PE20191843A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502575A1 (cg-RX-API-DMAC7.html)
SA (1) SA519410534B1 (cg-RX-API-DMAC7.html)
TW (4) TWI747043B (cg-RX-API-DMAC7.html)
WO (1) WO2018213113A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906954B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
EP4469558A4 (en) * 2022-01-29 2026-02-25 Hifibio Inc Anti-BTLA antibodies and their uses in cancer treatment
AU2023212896A1 (en) * 2022-01-29 2024-08-22 Hifibio, Inc. Antibody against btla and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4626929A2 (en) * 2022-12-02 2025-10-08 Eli Lilly and Company Btla agonist antibodies and uses thereof
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
WO2026053130A1 (en) * 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US7153950B2 (en) * 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
MX2009005189A (es) * 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス, インコーポレイテッド グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体

Similar Documents

Publication Publication Date Title
JP2021151253A5 (cg-RX-API-DMAC7.html)
JP2023538891A5 (cg-RX-API-DMAC7.html)
JP2020018311A5 (cg-RX-API-DMAC7.html)
AR120511A2 (es) Producción de proteínas heteromultiméricas
Xu et al. Progress, challenges and solutions of research on photosynthetic carbon sequestration efficiency of microalgae
Deska et al. Immobilized fungal laccase as" green catalyst" for the decolourization process–State of the art
JP2025508827A5 (cg-RX-API-DMAC7.html)
JP2022503959A5 (cg-RX-API-DMAC7.html)
RU2015148746A (ru) Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
JP2005120106A5 (cg-RX-API-DMAC7.html)
HRP20211882T1 (hr) Protutijela protiv cd40 i njihova upotreba
IL310186B1 (en) Plasma kallikrein binding proteins
CA2466629A1 (en) Expression control using variable intergenic sequences
JP2008500050A5 (cg-RX-API-DMAC7.html)
HRP20180155T1 (hr) Novo protutijelo protiv ljudskog ngf
JP2011024493A5 (cg-RX-API-DMAC7.html)
JP2025090679A5 (cg-RX-API-DMAC7.html)
JP2011505811A5 (cg-RX-API-DMAC7.html)
RU2010119558A (ru) Способ получения клетки, способной продуцировать гетепротеины с высоким выходом
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
JP2024523166A5 (cg-RX-API-DMAC7.html)
CN103184229A (zh) 重组蛋白a/g基因及其表达产物的制备、应用
Kuai et al. Rabbit monoclonal antibodies: Synergistic innovation and breakthrough based on B-cell development mechanism and single B-cell technology
RU2017105852A (ru) Способ повышения удельной скорости и продуцирования в эукариотических клетках
CN118824381A (zh) 收敛式dna自组装索引体系的构建方法及应用